A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

This new treatment could help bring relief for millions of Americans struggling with depression. The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

Major depression has one of the highest economic burdens of any psychiatric disorder,” he pointed out. Now, the FDA has also approved Spravato for treating adults with MDD who have not responded ...